Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
FreeMind Investments (FMI) is a venture capital fund established to focus on the life sciences industry. Founded in Boston, Massachusetts, FMI collaborates with strategic and limited partners to invest in research and development (R&D) initiatives. The organization leverages the expertise of FreeMind Group and Daewoong Pharma, providing a data-driven investment model that opens doors to various pharmaceutical deal-making opportunities. FMI has expanded its global presence with additional offices in Jerusalem, Israel, and Seoul, South Korea.
As of now, FMI manages a diverse portfolio of investments in the life sciences sector, with a strong emphasis on pre-clinical and clinical stage programs. The firm employs a proprietary investment formula that rigorously assesses both scientific and business potential, ensuring that they identify high-potential companies for successful exits. FMI's notable milestones include establishing a significant presence in the biotech and healthcare sectors, with a focus on companies that are poised for growth and innovation.
FreeMind Investments primarily invests in the life sciences sector, targeting companies at various stages of development, including pre-seed, seed, Series A, Series B, and Series C. The firm places particular emphasis on pre-clinical and clinical stage programs, utilizing a proprietary investment formula that rigorously evaluates scientific and business potential through comprehensive due diligence. FMI's geographic focus is predominantly on the United States (60%), followed by Europe (30%), and other regions such as Israel, Australia, and Canada (10%).
The organization aims to identify companies with a high likelihood of successful exits, such as initial public offerings (IPOs) or mergers and acquisitions (M&A). FMI seeks to partner with founders who demonstrate strong leadership and innovative approaches in the life sciences field, ensuring that their investments align with the firm’s strategic goals and expertise.
FMI's portfolio includes several notable companies in the life sciences sector:
Ram May-Ron: Founder & Managing Partner. Ram has extensive experience in venture capital and life sciences, having led multiple successful investments in the biotech sector.
B. Christopher Kim: Co-Founder & Venture Partner. Christopher brings a wealth of knowledge in healthcare investments and has a strong track record of identifying promising startups.
Ayal Ronen: Director. Ayal specializes in operational support for portfolio companies, leveraging his background in biotech to enhance company performance.
Alexandra Duev-Cohen: Principal. Alexandra focuses on deal sourcing and due diligence, ensuring that FMI invests in high-potential opportunities.
Jonathan Adalist: Principal. Jonathan has a strong background in life sciences and plays a key role in evaluating investment opportunities.
Michal Fefferman: Head of Operations. Michal oversees the operational aspects of FMI, ensuring efficient processes and support for portfolio companies.
To pitch FreeMind Investments, founders should send an email to info@freemindinvestments.com. A well-structured pitch deck is essential, including details on the business model, market opportunity, and scientific basis of the product or service. FMI appreciates concise and data-driven presentations that clearly outline the potential for growth and exit strategies.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
What are FreeMind Investments' investment criteria?
FMI focuses on the life sciences sector, particularly companies in pre-clinical and clinical stages. They look for high-potential companies that demonstrate strong scientific and business potential through rigorous due diligence.
How can I pitch to FreeMind Investments?
Founders can reach out via email at info@freemindinvestments.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and scientific basis of the product or service.
What makes FreeMind Investments different from other VCs?
FMI leverages the expertise of FreeMind Group and Daewoong Pharma, providing a data-driven investment model that enhances their ability to identify promising opportunities in the life sciences sector.
What is the geographic scope of FreeMind Investments?
FMI primarily invests in the United States (60%), Europe (30%), and other regions such as Israel, Australia, and Canada (10%).
What is the typical check size for investments?
While specific check sizes are not disclosed, FMI invests across various stages, including pre-seed, seed, Series A, B, and C, indicating a flexible approach to funding.
What kind of post-investment involvement does FreeMind Investments have?
FMI typically engages with portfolio companies through board involvement and operational support, leveraging their extensive network in the life sciences industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.